Drugs / Libevitug
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05542979 | Aug 2019 → Mar 2022 | chronic hepatitis B virus infection | Huahui Health | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT05861674 | Jun 2023 → Jul 2024 | hepatitis D virus infection | Huahui Health | Completed | No outcome recorded |
| Phase 2 | NCT05734807 | Jul 2022 → Apr 2024 | chronic hepatitis B virus infection | Huahui Health | Completed | No outcome recorded |
| Phase 2 | NCT05839639 | Oct 2021 → Dec 2022 | chronic hepatitis B virus infection | Huahui Health | Completed | No outcome recorded |
| Phase 2 | NCT05674448 | Aug 2021 → Jul 2022 | chronic hepatitis B virus infection | Huahui Health | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07499544 | Apr 2026 → Sep 2028 expected | hepatitis D virus infection | Huahui Health | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Libevitug | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07499544 ↗ |
| Known as | HH-003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05861674 ↗ |
| Action | Inhibit | “It blocks engagement of preS1 with sodium taurocholate co-transporting polypeptide (NTCP), the cellular receptor for HBV/HDV.” NCT05674448 ↗ |
| Modality | Monoclonal antibody | “which is a monoclonal antibody targeting Hepatitis B virus.” NCT05542979 ↗ |
| Route | Intravenous | “HH-003 injection is administrated via I.V. infusion” NCT05542979 ↗ |